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Arthritic diseases, such as osteoarthritis and rheumatoid arthritis, are associated with synovium 
inflammation (synovitis). Several pro-inflammatory cytokines, especially tumor necrosis factor-α (TNF-
α) and interleukins (IL), are important mediators of inflammation and articular cartilage destruction, 
supporting a potential possibility of anticytokine therapy in these diseases. IL-6 is one of the key 
regulators of the inflammatory response. Thus, human monoclonal antibodies against IL-6 may prevent 
its action, and consequently reduce inflammation after intra-articular (IA) injection. Indeed, several 
clinical trials have already demonstrated positive outcomes over disease progression. Although these 
treatments are very attractive, they are associated with limited efficacy because of the rapid clearance 
of antibodies by the synovium. A solution to overcome this problem is using nanoparticles (NPs) as a 
substrate to protect and extend the action of the antibodies. Natural-derived polymers, like chitosan (Ch) 
and hyaluronic acid (HA), are biocompatible and biodegradable polysaccharides, being HA a natural 
component of the extracellular matrix of articular cartilage. Therefore, biodegradable polymeric NPs 
represent a good candidate for IA administration. 
In the present work we propose natural biodegradable polymeric NPs biofunctionalized with immobilized 
antibodies that selectively capture and inactivate the pro-inflammatory cytokine IL-6, reducing synovium 
inflammation. Ch-HA NPs were successfully prepared by polyelectrolyte complexation and further 
stabilized through carbodiimide chemistry (ethyl(dimethylaminopropyl) carbodiimide (EDC)/N-
hydroxysuccinimide (NHS)). The particle size and zeta potential of the NPs were optimized. Stable NPs 
with 121.8 ± 2.4 of particle diameter, 0.11 ± 0.01 of polydispersity index and +25.12 ± 1.86 mV of zeta 
potential were produced with 0.25 mg/mL of initial polymers concentrations, at pH 5 and with 50/200 
mM of EDC/NHS concentration. The anti-IL-6 antibody was immobilized at the surface of Ch-HA NPs. 
After determining the maximum antibody immobilization ability (7 µg/mL), the capacity to capture the 
recombinant IL-6 was evaluated. The efficacy was around 94-97%. Biological assays demonstrated not 
only the cytocompatibility of the produced NPs with human articular chondrocytes (hACs) (Fig 1) and 
human macrophages, but also the benefits of the capture and inactivation of IL-6 after stimulation with 
monocyte-derived macrophage conditioned medium. In conclusion, it is foreseeable that these NPs will 
overcome the limitations of the abovementioned treatments, since such NPs will increase the 
therapeutic efficacy due to their subcellular size, non-toxicity and high stability, being a promising 
approach for the local and sustained treatment of arthritic diseases. 
 
Fig 1. Biological 
performance of the hACs cultured 
with 
NPs (a) cell viability, 
(b) SEM micrographs, 
and (c) confocal 
microscopy with NPs 
at 50 µg/mL. 
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